KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) Enterprise Value (2016 - 2025)

Ionis Pharmaceuticals has reported Enterprise Value over the past 17 years, most recently at -$2.7 billion for Q4 2025.

  • Quarterly results put Enterprise Value at -$2.7 billion for Q4 2025, down 16.53% from a year ago — trailing twelve months through Dec 2025 was -$2.7 billion (down 16.53% YoY), and the annual figure for FY2025 was -$2.7 billion, down 16.53%.
  • Enterprise Value for Q4 2025 was -$2.7 billion at Ionis Pharmaceuticals, down from -$2.2 billion in the prior quarter.
  • Over the last five years, Enterprise Value for IONS hit a ceiling of -$1.8 billion in Q1 2021 and a floor of -$2.7 billion in Q4 2025.
  • Median Enterprise Value over the past 5 years was -$2.2 billion (2024), compared with a mean of -$2.2 billion.
  • Biggest five-year swings in Enterprise Value: grew 16.28% in 2021 and later decreased 17.98% in 2023.
  • Ionis Pharmaceuticals' Enterprise Value stood at -$2.1 billion in 2021, then grew by 6.06% to -$2.0 billion in 2022, then dropped by 17.33% to -$2.3 billion in 2023, then rose by 1.44% to -$2.3 billion in 2024, then dropped by 16.53% to -$2.7 billion in 2025.
  • The last three reported values for Enterprise Value were -$2.7 billion (Q4 2025), -$2.2 billion (Q3 2025), and -$2.3 billion (Q2 2025) per Business Quant data.